This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
PharmaPoint: Rheumatoid Arthritis - India Drug Forecast and Market Analysis Event-Driven Update
GlobalData has released its new Country report, "PharmaPoint: Rheumatoid Arthritis - India Drug Forecast and Market Analysis Event-Driven Update". The RA market is currently very dynamic, with the
November 6, 2012 FDA approval of Pfizer's Xeljanz (tofacitinib) and novel oral therapies awaiting approval such as: Eli Lilly's anti-BAFF, tabalumab and JAK1,2 inhibitor, baricitinib, and Rigel/AZ's SYK inhibitor, fostamatinib. These compounds will challenge the current biologics in the attempt to dislodge the stronghold of the TNF inhibitors, if their safety and efficacy profiles are proven once they enter the market.
Indian physicians included in our study typically follow guidelines such as ACR or EULAR, but also follow their own clinical experience. In
India, the process to diagnosis a patient with RA usually begins with the PCP or GP regardless of which potential stage the patient is in, then progresses with the referral to a rheumatologist for further diagnosis and treatment as this occurs about 32% of the time. Also, most people seeking treatment are within the 35-55-year-old group. Within this age group, females and males are equally distributed according to our physician experts.
Scope - Overview of RA, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in
India including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in
India from 2011 to 2022.
- Analysis of the impact of key events as well the drivers and restraints affecting the
India rheumatoid arthritis market.
Reasons to buy - Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for rheumatoid arthritis